

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Gravis Energy Corp. (the “Company”)
950-1130 West Pender Street
Vancouver, B.C. V6E 4A4

Item 2 Date of Material Change

August 23, 2017

Item 3 News Release

A news release was disseminated on August 30, 2017 through the facilities of Stockwatch.

Item 4 Summary of Material Change

The Company has received conditional acceptance from the Canadian Securities Exchange for its proposed acquisition of all of the issued and outstanding securities of BiocurePharm Corporation (“**Biocure**”), a private Korean biopharmaceutical company (the “**Transaction**”).

Item 5 Full Description of Material Change

The Company has received conditional acceptance for the Transaction from the CSE, which is a ‘fundamental change’ within the meaning of the applicable policies of the CSE.

The conditions for the Company to receive the final approval of the CSE include obtaining shareholder approval and submitting all final remaining listing documentation and fees. The Company intends to seek shareholder approval by way of written consent, which it expects to receive within the next 14 days.

As previously announced, prior to the closing, the Company will consolidate its share capital on a 6.033479 old for one new basis (the “**Consolidation**”) and will acquire all of the issued and outstanding securities of BiocurePharm in consideration of the issuance of common shares of the Company on the basis of 24 post-Consolidation common shares of the Company being issued for each share of BiocurePharm held. Upon completion of the Transaction, the Company will change its name to “**Biocure Technology Inc.**” and its stock symbol will be changed to “**CURE**”. The Company will announce the effective dates for the Consolidation and change of name once finalized.

The Company anticipates that the closing of the Transaction will occur late in September to allow sufficient time for the corporate law procedures by which the Company will acquire BiocurePharm to be completed under Korean law. The Company’s shares will remain halted until the final approval of the CSE is received.

Item 6 **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7 **Omitted Information**

No information has been omitted on the basis that it is confidential information.

Item 8 **Executive Officer**

Julie Hajduk is knowledgeable about the material change and the Report and may be contacted (778) 331.3816.

Item 9 **Date of Report**

August 30, 2017